- Home
- UAN vs COGT Comparison
UAN vs COGT Comparison
Compare UAN & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UAN
- COGT
- Stock Information
- Founded
- UAN 2007
- COGT 2014
- Country
- UAN United States
- COGT United States
- Employees
- UAN N/A
- COGT N/A
- Industry
- UAN Agricultural Chemicals
- COGT Biotechnology: Pharmaceutical Preparations
- Sector
- UAN Industrials
- COGT Health Care
- Exchange
- UAN Nasdaq
- COGT Nasdaq
- Market Cap
- UAN 930.2M
- COGT 1.1B
- IPO Year
- UAN 2011
- COGT 2018
- Fundamental
- Price
- UAN $94.10
- COGT $15.52
- Analyst Decision
- UAN
- COGT Strong Buy
- Analyst Count
- UAN 0
- COGT 11
- Target Price
- UAN N/A
- COGT $21.20
- AVG Volume (30 Days)
- UAN 20.1K
- COGT 2.1M
- Earning Date
- UAN 10-27-2025
- COGT 11-11-2025
- Dividend Yield
- UAN 7.17%
- COGT N/A
- EPS Growth
- UAN 77.68
- COGT N/A
- EPS
- UAN 8.32
- COGT N/A
- Revenue
- UAN $576,184,000.00
- COGT N/A
- Revenue This Year
- UAN N/A
- COGT N/A
- Revenue Next Year
- UAN N/A
- COGT N/A
- P/E Ratio
- UAN $11.37
- COGT N/A
- Revenue Growth
- UAN 8.15
- COGT N/A
- 52 Week Low
- UAN $62.94
- COGT $3.72
- 52 Week High
- UAN $98.99
- COGT $16.22
- Technical
- Relative Strength Index (RSI)
- UAN 64.09
- COGT 71.71
- Support Level
- UAN $90.14
- COGT $13.72
- Resistance Level
- UAN $94.99
- COGT $16.22
- Average True Range (ATR)
- UAN 1.48
- COGT 0.69
- MACD
- UAN 0.44
- COGT 0.24
- Stochastic Oscillator
- UAN 84.62
- COGT 85.02
About UAN CVR Partners LP Common Units representing Limited Partner Interests
CVR Partners LP is a manufacturer and supplier of nitrogen fertilizer products. Its principal products include Urea Ammonium Nitrate (UAN) and ammonia. The company market ammonia products to industrial and agricultural customers and UAN products to agricultural customers. The primary geographic markets for its fertilizer products are Kansas, Missouri, Nebraska, Iowa, Illinois, Colorado, and Texas. The company's product sales are heavily weighted toward UAN.
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.